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S U M M A R Y
Objectives: About 2% of the world population is infected with hepatitis C virus (HCV), a leading cause of
hepatic cirrhosis and hepatocellular carcinoma. The Niemann–Pick C1-like 1 cholesterol absorption
receptor (NPC1L1) was recently identiﬁed to be an important factor for HCV entry into host cells.
Whether genetic variations of the NPC1L1 gene are associated with HCV infection is unknown.
Methods: In this study, ﬁve single nucleotide polymorphisms (SNPs) of the NPC1L1 gene were analyzed
in 261 HCV-infected individuals and 265 general controls from Yunnan Province, China.
Results: No signiﬁcant differences were identiﬁed in genotypes or alleles of the SNPs between the two
groups. After constructing haplotypes based on the ﬁve SNPs, a signiﬁcant difference between HCV-
infected individuals and general controls was shown for two haplotypes. Haplotype GCCTT appeared to
be a protective factor and haplotype GCCCT was a risk factor for HCV-infected individuals. Genotypes of
four SNPs correlated with biochemical characteristics of HCV-infected persons. Genotypes of SNPs
rs799444 and rs2070607 were correlated with total bilirubin. Genotype TT of rs917098 was a risk factor
for the gamma-glutamyltransferase level. Furthermore, HCV-infected individuals carrying genotype GG
of rs41279633 showed statistically higher gamma-glutamyltransferase levels than HCV-infected
persons with GT and TT.
Conclusion: The results of this study identiﬁed the association between genetic susceptibility of the
NPC1L1 gene and HCV infection, as well as biochemical characteristics of HCV-infected persons in
Yunnan, China.
 2016 The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
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Hepatitis C, a type of inﬂammation of the liver caused by
hepatitis C virus (HCV), is the most common chronic hepatic
disease worldwide.1 About 2% of the world population is infected
with HCV, and the rate of HCV infection is higher in developing
countries than in developed countries.2 China is a developing
country and the Chinese people account for one-ﬁfth of the world* Corresponding author. Tel./fax: +86 871 65920756.
E-mail addresses: zam1980@yeah.net (A.-M. Zhang), oliverxia2000@aliyun.com
(X. Xia).
http://dx.doi.org/10.1016/j.ijid.2016.10.007
1201-9712/ 2016 The Author(s). Published by Elsevier Ltd on behalf of International S
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).population; thus studying the mechanisms of HCV infection and its
pathogenicity in Chinese population is important and necessary to
control the incidence of HCV infection.
Certain genetic factors have been identiﬁed to play a vital role in
HCV infection, spontaneous viral clearance, and the response to
treatment.3–7 Among these factors, polymorphisms in the inter-
leukin 28B (IL28B) gene could affect the clearance rate of HCV in
different populations.5–7 However, this research did not complete-
ly explain how the host genetic factors inﬂuenced HCV infection or
the pathogenic process.
Humans and chimpanzees are the natural hosts of HCV. Entry
into the host is the ﬁrst step in HCV infection, so certain special
factors must be present in these two species to mediate thisociety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
Figure 1. Linkage disequilibrium (LD) map of single nucleotide polymorphisms
(SNPs) in the NPC1L1 gene. The frequency of each SNP was downloaded from the
HapMap website (http://hapmap.ncbi.nlm.nih.gov/). Black squares indicate high LD
as measured by r2; LD becomes lower with a gradually lighter color. The numerical
value in each individual square refers to the r2 value for each SNP pair. The four SNPs
analyzed in this study are framed in red.
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including the tetraspanin molecule CD81 (CD81),8 scavenger
receptor class B member I (SR-BI),9 tight-junction protein claudin
1 (CLDN1),10 occludin (OCLN),11 etc. These proteins could be
considered targets for anti-HCV drugs.12
A new and vital entry factor, Niemann–Pick C1-like 1 cholesterol
absorption receptor (NPC1L1), was recently identiﬁed.13 The
function of NPC1L1 protein is cholesterol absorption and
cholesterol homeostasis. High expression levels in the intestines
of many species and in hepatocytes in humans have been shown.
The cholesterol level in cells has been shown to be associated with
HCV infection.14,15 Furthermore, genetic variations in the NPC1L1
gene could inﬂuence cholesterol absorption, levels of low-density
lipoprotein cholesterol (LDL-C), and the response to ezetimibe.16,17
These studies suggest that genetic variations in the NPC1L1 gene
might play a role in HCV infection.
To test this hypothesis, ﬁve single nucleotide polymorphisms
(SNPs) of the NPC1L1 gene were analyzed in 261 patients with an
HCV infection and 265 matched general controls. The results
showed no associations between genotypes or alleles of each SNP
and HCV infection, but the haplotypes constructed by them
seemed to be protective factors or risk factors for HCV infection in
the Chinese population.
2. Materials and methods
2.1. Individuals
All HCV-infected persons and controls were recruited by
doctors at the First People’s Hospital of Yunnan Province from
October 2012 to September 2013, as reported in a previous study.18
The presence of HCV infection was determined by ELISA and the
colloidal gold method; 261 HCV-positive patients and 265 HCV-
negative general controls were identiﬁed. Biochemical indices
were obtained for all patients and controls, including gamma-
glutamyltransferase (GGT), alanine aminotransferase (ALT), aspar-
tate aminotransferase (AST), the ALT/AST ratio, albumin (ALB),
total bilirubin (TBIL), and high-density lipoprotein cholesterol
(HDL-C).18 The controls were sex- and age-matched to the HCV-
infected persons. The mean  standard deviation age of the HCV
patients was 48.19  14.85 years and of controls was
39.39  9.32 years. The sex ratio (male/female) was 1:2.5 (74/187)
in the HCV-infected cohort and 1:2.7 (71/194) in the control cohort.
All HCV-infected subjects had a chronic HCV infection and had
not undergone any treatment. The Hepatitis B Viral DNA Quantita-
tive Fluorescence Diagnostic Kit (RT-PCR-Fluorescent Probing;
Sansure, China) and Anti-HIV ELISA Kit (Wantai, China) were used
to detect hepatitis B virus (HBV) and HIV in all individuals in this
study. The HCV-infected persons had no other hepatic disease.
Written informed consent was obtained from each participant
prior to the study, conforming to the tenets of the Declaration of
Helsinki. The institutional review board of Kunming University of
Science and Technology approved this study.
2.2. SNP selection and genotyping
The linkage disequilibrium (LD) map of all SNPs in the NPC1L1
gene region (chr. 7: 44 518–44 548 kb) was constructed using
Haploview software19 and data from HapMap (http://hapmap.
ncbi.nlm.nih.gov/, CHB + JPT) (Figure 1). Four tag SNPs (rs2070607,
rs917098, rs17134029, and rs799444) and one general SNP
(rs41279633; located in the 50 untranslated region (50UTR) of
the NPC1L1 gene) were selected and genotyped in this study,
according to the LD pattern and the criterion that the minor allele
frequency of the SNP should be more than 2%. These ﬁve SNPs were
genotyped using the SNaPshot assay; the genotyping results wereveriﬁed by sequencing 15% of the total samples (the primers are
listed in the Supplementary Material, Table S1). Haplotypes based
on the ﬁve SNPs were constructed using Phase software (Stephens
and Donnelly, University of Chicago, IL, USA; 2003).
2.3. Hepatitis C virus detection
HCV RNA was extracted from 100 ml of each HCV patient’s
serum using a TIANamp Virus RNA Kit (Tiangen, China), following
the manufacturer’s instructions. The HCV viral load was deter-
mined using the One Step PrimeScript RT-PCR Kit and Takara
Thermal Cycler Dice Real Time System TP800 (TaKaRa, Japan). The
sequences of the forward and reverse primers were 50-TGCTCAT-
GATGCACGGTCTAC-30 and 50-TGCGGAACCGGTGAGTACA-30, re-
spectively. The sequence of the probe for HCV detection was
FAM-5-CACCCTATCAGGCAGTACCACAAGGCC-3-TAMRA. The PCR
procedure was as follows: 42 8C for 5 min, 95 8C for 10 s, and
35 cycles of 95 8C for 5 s and 58 8C for 45 s.
2.4. Statistical analysis
The differences in genotypes and alleles of each SNP and
haplotype between patients and normal controls were evaluated
using Pearson’s Chi-square test. The odds ratio (OR) and 95%
conﬁdence intervals (95% CI) were calculated. The Student t-test
(unpaired, two-tailed) was used to analyze differences in biochem-
ical characteristics in patients with different genotypes of each SNP.
Correlation analysis was used to analyze the association between
HCV RNA levels and biochemical characteristics of HCV-infected
individuals. The statistical analysis was performed using SPSS
version 18.0 software package (SPSS Inc., Chicago, IL, USA). A p-
value of <0.05 was considered statistically signiﬁcant.
2.5. Data availability
The authors state that all data necessary to conﬁrm the
conclusions presented in this article are represented fully within
the article.
Table 1
Analysis of genotypes and alleles of the ﬁve selected SNPs in HCV-infected patients and general controls
SNP (genotype/allele) HCV patients (n = 261) General controls (n = 265) p-Value OR (95% CI)
rs2070607
AA 1 1 0.991 1.015 (0.06–16.32)
AG 21 19 0.705 1.133 (0.59–2.16)
GG 239 245 0.709 0.887 (0.47–1.67)
A 23 21 0.719 1.117 (0.61–2.04)
G 499 509 0.895 (0.49–1.64)
rs917098
CC 37 39 0.860 0.957 (0.59–1.56)
CT 128 130 0.997 0.999 (0.71–1.41)
TT 96 96 0.895 1.024 (0.72–1.46)
C 202 208 0.855 0.977 (0.76–1.25)
T 320 322 1.023 (0.80–1.31)
rs17134029
AA 0 2 0.160
AC 23 16 0.225 1.504 (0.78–2.92)
CC 238 247 0.388 0.754 (0.40–1.43)
A 23 20 0.604 1.175 (0.64–2.17)
C 499 510 0.851 (0.46–1.57)
rs799444
CC 133 131 0.727 1.063 (0.76–1.50)
CT 112 113 0.950 1.011 (0.72–1.43)
TT 16 21 0.421 0.759 (0.39–1.49)
C 378 375 0.551 1.085 (0.83–1.42)
T 144 155 0.922 (0.70–1.21)
rs41279633
GG 248 252 0.968 0.984 (0.45–2.17)
GT 13 12 0.807 1.105 (0.50–2.47)
TT 0 1 0.301 –
G 509 516 0.877 1.062 (0.49–2.28)
T 13 14 0.941 (0.44–2.02)
SNP, single nucleotide polymorphism; HCV, hepatitis C virus; OR, odds ratio; CI, conﬁdence interval.
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None of the individuals in this study was co-infected with HBV
and/or HIV. Genetic variations of the interferon lambda gene (IFNl)
in the HCV-infected patients and general controls were analyzed in
a previous study; no population deviation in HCV-infected patients
and controls was found.18 The ﬁve SNPs could cover the range of
the NPC1L1 gene, as the principle for selection (Figure 1), but no
association was found between any genotype or allele of single
variation in the NPC1L1 gene and HCV infection (Table 1).
The HCV viral load was obtained from 81 HCV-infected persons.
The HCV RNA level of genotypes of each SNP were compared, but
no signiﬁcant difference was identiﬁed. No association was found
between the HCV RNA level and biochemical characteristics of the
HCV-infected persons using correlation analysis.
As no signiﬁcant difference in each SNP was found between
HCV-infected persons and general controls, the two cohorts were
pooled to calculate the allele frequency of the ﬁve SNPs in this
study. The minor allele frequency of rs2070607, rs917098,
rs17134029, and rs799444 was 4.2%, 39%, 4.1%, and 28.4%,Table 2
Analysis of haplotypes constructed with ﬁve SNPs in HCV patients and general control
Haplotype HCV patients Controls 
GCCCG 114 109 
GTCCG 242 256 
GTCTG 52 44 
GTATG 22 20 
GCCTG 56 71 
ACCTG 13 11 
ACCCG 9 5 
GCCCT 9 0 
GCCTT 0 7 
Others 5 7 
SNP, single nucleotide polymorphism; HCV, hepatitis C virus; OR, odds ratio; CI, conﬁdrespectively. These frequencies are somewhat different from those
of CHB in HapMap (minor allele frequency of rs2070607, rs917098,
rs17134029, and rs799444 are 6%, 37%, 8%, and 34%, respectively).
The allele frequency of SNP rs41279633 was 2.7% for allele T and
97.3% for allele G. No data for rs41279633 were available from
HapMap. These results suggest that genetic variations differ in
different populations.
Haplotypes were constructed using the ﬁve SNPs and Haplo-
view software for HCV patients and general controls. A total of
11 haplotypes were constructed for the HCV-infected population
and 10 for general controls. All haplotypes for which the number
was more than ﬁve in either the HCV-infected population or
general controls were compared between the two groups (Table 2).
A signiﬁcant difference between the groups was found for two
haplotypes. One of the haplotypes (GCCTT) showed a signiﬁcantly
lower frequency in HCV patients (0%, 0/522) than in controls (1.3%,
7/530), and might protect persons from HCV infection (p = 0.008).
The frequency of the other haplotype (GCCCT) was signiﬁcantly
higher in HCV patients (1.7%, 9/522) than in general controls (0%, 0/
530), and might increase the risk of HCV infection (p = 0.002). Thiss
p-Value OR 95% CI
0.613 1.079 0.803–1.451
0.528 0.925 0.726–1.178
0.350 1.222 0.802–1.862
0.715 1.122 0.605–2.082
0.184 0.777 0.535–1.128
0.652 1.205 0.535–2.715
0.270 1.842 0.613–5.534
0.002 – –
0.008 – –
0.579 0.723 0.228–2.291
ence interval.
Table 3
Analysis of biochemical characteristics in HCV-infected individuals and general controls
SNP (genotypes)/biochemical characteristics GGT ALT AST ALB TBIL HDL-C
rs917098 CC General controls 34.08  13.08 28.92  5.24 35.18  3.72 46.91  0.34 13.97  1.00 1.35  0.08
HCV-infected persons 45.95  6.84 61.76  10.01 57.30  6.09 45.16  0.53 15.81  1.38 1.14  0.08
p-Value 0.431 0.004 0.003 0.007 0.281 0.067
CT General controls 22.95  2.64 29.15  1.99 35.14  1.23 46.79  0.23 13.69  0.38 1.37  0.04
HCV-infected persons 59.88  5.27 62.93  4.40 60.09  3.23 45.52  0.28 15.12  0.49 1.27  0.04
p-Value <0.0001 <0.0001 <0.0001 0.0005 0.022 0.088
TT General controls 20.50  2.32 22.53  1.51 31.75  0.71 46.40  0.27 13.45  0.51 1.43  0.05
HCV-infected persons 75.96  9.18 74.60  6.31 68.64  4.46 45.73  0.25 23.04  8.26 1.31  0.05
p-Value <0.0001 <0.0001 <0.0001 0.072 0.248 0.068
rs799444 CC General controls 23.95  4.22 26.83  2.14 34.38  1.40 46.82  0.22 13.76  0.43 1.36  0.04
HCV-infected persons 66.66  6.85 63.99  4.32 62.23  3.56 45.53  0.26 21.76  5.97 1.27  0.04
p-Value <0.0001 <0.0001 <0.0001 0.0002 0.185 0.121
CT General controls 22.58  2.95 25.92  1.93 33.51  1.13 46.41  0.24 13.64  0.47 1.38  0.04
HCV-infected persons 60.55  5.90 69.86  5.67 62.61  3.35 45.50  0.27 14.58  0.49 1.24  0.04
p-Value <0.0001 <0.0001 <0.0001 0.012 0.169 0.017
TT General controls 28.19  5.13 29.52  3.64 33.19  2.09 47.04  0.59 12.99  0.91 1.61  0.12
HCV-infected persons 63.27  14.51 73.13  19.83 70.00  13.72 46.05  0.84 12.69  1.31 1.45  0.12
p-Value 0.015 0.016 0.004 0.329 0.851 0.366
rs2070607 AA/AG General controls 46.40  25.02 28.15  5.97 33.45  2.94 46.86  0.65 14.39  1.50 1.44  0.10
HCV-infected persons 62.00  12.15 61.23  12.47 57.45  5.56 44.86  1.00 13.43  0.72 1.25  0.11
p-Value 0.567 0.026 0.0006 0.109 0.557 0.236
GG General controls 21.84  1.72 26.60  1.40 33.96  0.90 46.65  0.16 13.59  0.30 1.39  0.03
HCV-infected persons 63.99  4.67 67.59  3.63 63.33  2.62 45.61  0.17 18.57  3.33 1.27  0.03
p-Value <0.0001 <0.0001 <0.0001 <0.0001 0.133 0.006
rs17134029 AA/AC General controls 21.22  5.15 27.33  4.73 36.22  4.08 46.42  0.89 13.16  1.09 1.46  0.11
HCV-infected persons 75.61  16.09 70.74  10.32 67.70  7.64 45.07  0.78 15.57  1.29 1.21  0.10
p-Value 0.006 0.001 0.002 0.260 0.176 0.111
CC General controls 23.88  2.62 26.68  1.43 33.75  0.87 46.68  0.16 13.68  0.31 1.39  0.03
HCV-infected persons 62.68  4.56 66.70  3.69 62.37  2.58 45.59  0.18 18.38  3.35 1.27  0.03
p-Value <0.0001 <0.0001 <0.0001 <0.0001 0.155 0.008
rs41279633 GG General controls 22.65  2.35 26.55  1.39 33.97  0.88 46.67  0.16 13.72  0.31 1.39  0.03
HCV-infected persons 63.56  4.56 67.20  3.57 62.92  2.53 45.69  0.17 18.26  3.21 1.28  0.03
p-Value <0.0001 <0.0001 <0.0001 <0.0001 0.156 0.013
GT/TT General controls 43.92  21.13 28.77  7.20 32.92  3.62 46.62  0.87 12.21  1.18 1.49  0.14
HCV-infected persons 68.69  15.51 64.38  15.81 61.38  8.97 42.72  1.41 15.62  2.14 1.01  0.14
p-Value 0.354 0.051 0.007 0.027 0.174 0.023
HCV, hepatitis C virus; SNP, single nucleotide polymorphism; GGT, gamma-glutamyltransferase; ALT, alanine aminotransferase; AST, aspartate aminotransferase; ALB,
albumin; TBIL, total bilirubin; HDL-C, high density lipoprotein cholesterol.
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associated with HCV infection.
Because the number of some genotypes was less than ﬁve in
three of the SNPs (genotype AA of rs2070607, genotype TT of
rs41279633, and genotype AA of rs17134028), the biochemical
features were analyzed after combining the two genotypes with
lower frequencies. Genotype AA of rs2070607 was combined with
genotype AG, genotype TT of rs41279633 was combined with
genotype GT, and genotype AA of rs17134028 was combined with
genotype AC.
Signiﬁcant differences between HCV-infected individuals and
general controls with the same genotype were found for most of
the biochemical characteristics (Table 3). The GGT level was
similar in HCV-infected persons and controls with genotype CC of
rs917098, genotype AA/AG of rs2070607, and genotype GT/TT of
rs41279633. HCV patients and general controls with genotype TT
of rs917098 and rs799444, genotype AA/AG of rs2070607, and
genotype AA/AC of rs17134029 had similar ALB levels. With the
exception of persons with genotype CT of rs917098 in the HCV-
infected and control groups, there was no signiﬁcant difference
between the two cohorts in TBIL levels. The HDL-C level differed
signiﬁcantly between HCV-infected individuals and controls with
genotype CT of rs799444, genotype GG of rs2070607, genotype CC
of rs17134029, and all genotypes of rs41279633. These results
suggest that genotypes of SNPs in the NPC1L1 gene could inﬂuence
the biochemical characteristics of HCV-infected persons.
When the difference between genotypes in HCV-infected
individuals was studied, an association between biochemical
characteristics and SNPs of the NPC1L1 gene in the HCV-infectedpopulation of Yunnan was identiﬁed (Figure 2). The TBIL level was
signiﬁcantly lower in genotype TT of rs799444 and genotype AA/
AG of rs2070607 than in genotype CC of rs799444 (p = 0.029) and
genotype GG of rs2070607 (p = 0.033). Genotype TT of rs917098
seemed to be a risk factor for the GGT level in HCV-infected
individuals, but genotype CC might be protective (p = 0.010). There
was a statistically signiﬁcant difference in ALB level between
genotype GG and GT/TT of rs41279633 (p = 0.0003). The level of
ALB was higher for genotype GG than for genotype GT/TT.
4. Discussion
The function of NPC1L1 is to mediate cholesterol absorption,
and its expression proﬁle in the human is tissue-speciﬁc (only in
gastrointestinal and hepatic tissue). The anti-cholesterol drug
ezetimibe has been shown to decrease plasma cholesterol levels by
blocking NPC1L1.20 Some studies have reported genetic variations
in the NPC1L1 gene to be associated with cholesterol absorption,
plasma cholesterol levels,21,22 and coronary heart disease.23
NPC1L1 was recently identiﬁed to be an important protein for
HCV entry into host hepatic cells.13 Whether genetic variations in
the NPC1L1 gene could inﬂuence HCV infection has not yet been
demonstrated.
In this study, ﬁve SNPs in the NPC1L1 gene in an HCV-infected
population from Yunnan, China were analyzed. This is the ﬁrst
study to investigate the allele frequency of SNPs in the NPC1L1 gene
in the population of Yunnan. Although the frequencies were
somewhat different from those of CHB in HapMap, the frequency
distribution of each SNP was similar.
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Figure 2. Comparisons of the levels of total bilirubin (TBIL), gamma-glutamyltransferase (GGT), and albumin (ALB) between the different genotypes of HCV in HCV-infected
persons. The levels of TBIL in HCV-infected persons with genotypes CC and TT of rs799444 (A), and with genotypes AA/AG and GG of rs2070607 (B) differed signiﬁcantly. The
levels of GGT in HCV-infected persons with genotypes CC and TT of rs917098 (C) differed signiﬁcantly. The levels of ALB in HCV-infected persons with genotypes GG and GT/TT
of rs41279633 (D) differed signiﬁcantly.
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rs4720470 in different populations.24,25 Osaki et al. analyzed the
genotype and allele frequencies of these two SNPs in Japanese
HCV-infected patients, but no association was found in that
study.26 The reasons for the difference between their results and
those of the present study might be as follows. Firstly, the SNPs
were different in the two studies. Four tag SNPs and one general
SNP were analyzed in the present study, and this was the ﬁrst time
that the association between these ﬁve SNPs and HCV-infected
patients in China has been analyzed. Secondly, the population was
different in the two studies. Although Chinese and Japanese
patients are all East Asian, their genetic susceptibility is distinct.
Thirdly, only genotype and allele frequencies of the SNPs in HCV-
infected persons were analyzed in the study by Osaki et al.
Haplotype frequencies were analyzed in the present study to
further reveal the correlation between NPC1L1 and HCV infection
for the whole NPC1L1 gene region. However, the number of
haplotypes for which a signiﬁcant difference between HCV-
infected persons and controls was found was small; more HCV-
infected samples should be collected to further verify the results.
Finally, only 80 HCV patients were assessed in the study of Osaki
et al., and the small sample size may lead to a population deviation.
Genetic variations in the host could affect the treatment of HCV
patients.6,7,18 Although no signiﬁcant difference was identiﬁed
between each SNP and HCV infection, genotypes of the genetic
variations were correlated with the biochemical characteristics in
the HCV-infected persons from Yunnan. Three of the correlated
biochemical characteristics (TBIL, GGT, and ALB) are markers of
liver function. This suggests that SNPs in the NPC1L1 gene might
inﬂuence the progression or treatment of HCV infection.
That humans and chimpanzees are the natural hosts of HCV
infection suggests that there must be certain special factors that
assist HCV entry into the host cells. CD81, SR-B1, OCLN, and CLDN1
are banded with HCV proteins and are required for HCV
entry.8,10,27,28 Other important proteins related to HCV entry haverecently been identiﬁed.13,29 Studies have been performed to
conﬁrm the roles of these proteins, but whether genetic
polymorphisms of these genes could inﬂuence HCV infection is
unknown. Although the number of HCV patients included in this
study was a limitation, these results could provide a theoretical
basis for the control and treatment of HCV infection. More studies
should be performed to determine the relationships between the
genetic susceptibility of these entry genes, HCV genotypes, HCV
viral load, and HCV infection, progression, and treatment effect in
HCV patients.
In conclusion, in this study it was found that genetic
polymorphisms of the NPC1L1 gene were associated with HCV
infection and biochemical characteristics of HCV-infected individ-
uals in Yunnan, China. More studies with larger numbers of HCV-
infected persons should be performed to verify the results.
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